Allogene Therapeutics Stock Price, News & Analysis

Allogene Therapeutics (Nasdaq: ALLO) and SpringWorks Therapeutics (Nasdaq: SWTX) have initiated a Phase 1 trial for ALLO-715, an investigational anti-B-cell maturation antigen (BCMA) AlloCAR T therapy, combined with SpringWorks’ nirogacestat, in patients with relapsed or refractory multiple myeloma. The trial aims to evaluate safety, tolerability, and preliminary efficacy. This is the first clinical study of its kind and represents a significant step in addressing the limited options for patients with this incurable cancer. Allogene is sponsoring the trial as part of its UNIVERSAL study.

Allogene Therapeutics (Nasdaq: ALLO) recently showcased preclinical data at the AACR Annual Meeting, revealing that its TurboCAR™ technology platform can enhance treatment efficacy for solid tumors by selectively activating cytokine signaling in CAR T cells. New TurboCAR constructs respond to PDL1/2, enabling them to overcome immunosuppressive challenges in the tumor microenvironment. This advancement could broaden the applicability of AlloCAR T™ therapies, positioning Allogene as a leader in both hematologic and solid tumor treatments.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) reported significant updates during the recent ASH meeting, showcasing initial data from its ALLO-715 AlloCAR T therapy for relapsed/refractory multiple myeloma. The Phase 1 UNIVERSAL trial demonstrated a 60% overall response rate with 40% achieving a very good partial response. The company ended 2020 with $1 billion in cash and plans to submit multiple IND applications in 2021. Financial guidance predicts operating expenses between $300 million and $330 million, reflecting continued investment in innovative CAR T therapies.

Allogene Therapeutics (Nasdaq: ALLO) plans to report its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. A live audio webcast and conference call will follow at 2:00 PM PT/5:00 PM ET. Investors can access the webcast on the company's website. Allogene focuses on developing allogeneic CAR T therapies to provide more accessible cancer treatments. The press release emphasizes the company's commitment to delivering 'off-the-shelf' therapies at scale.

Allogene Therapeutics (Nasdaq: ALLO) announced plans to participate in four virtual investor conferences in February and March 2021. Key events include the Guggenheim Healthcare Talks on February 11, the Cowen 41st Annual Health Care Conference on March 3, the 33rd Annual Roth Conference on March 15, and Oppenheimer's 31st Annual Healthcare Conference on March 16. These events will showcase Allogene's progress in developing allogeneic CAR T therapies for cancer. Webcast details and replays will be available on the company's website.

Allogene Therapeutics (Nasdaq: ALLO) announced that Dr. Ton Schumacher has received the 2021 Jeantet-Collen Prize for Translational Medicine. This award acknowledges his advancements in cancer immunotherapy and the understanding of immune responses to cancer cells. Schumacher's work is expected to enhance cancer diagnosis and treatment. As a leading researcher and chair of Allogene’s Scientific Advisory Board, his leadership is vital as the company develops innovative AlloCAR T™ therapies. The award includes funding for his ongoing research into tumor antigens and immune microenvironments.

Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. Pacific Time. David Chang, M.D., Ph.D., the company's President and CEO, will lead the presentation. A live webcast will be available on Allogene's website with a replay accessible for 30 days. The company focuses on developing allogeneic CAR T therapies, aiming to provide readily available cancer treatments at scale.

Allogene Therapeutics (Nasdaq: ALLO) has announced that the FDA has approved its IND application to study ALLO-715 in combination with nirogacestat for multiple myeloma patients. This Phase 1 clinical trial, part of Allogene's strategy to target BCMA, is expected to begin enrollment in Q1 2021. The combination aims to enhance the effectiveness of ALLO-715 by preventing BCMA cleavage, potentially leading to improved patient responses. The collaboration with SpringWorks Therapeutics is pivotal for this study, with Allogene assuming development costs.

Allogene Therapeutics and Overland Pharmaceuticals have formed a joint venture called Allogene Overland Biopharm to develop AlloCAR T™ therapies for hematologic malignancies and solid tumors in Greater China, Taiwan, South Korea, and Singapore. Overland will invest $117 million, including a $40 million upfront payment. The venture aims to accelerate the availability of these therapies in Asia, with Allogene providing technical expertise and Overland offering operational support. Allogene retains global rights for their investigational candidates and will receive milestone payments upon regulatory approvals.